Form 4: Anixa Biosciences Director Acquires 6,000 Shares in Open Market Purchase

Anixa Biosciences director, Lewis H. Titterton Jr., purchased 6,000 shares of common stock at $2.59 per share on January 21, 2025.

Summary

• On January 21, 2025, Lewis H. Titterton Jr., a director at Anixa Biosciences, acquired 6,000 shares of the company's common stock.
• The shares were purchased at a price of $2.59 each.
• Following this transaction, Mr. Titterton directly owns 928,334 shares of Anixa Biosciences common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a director's purchase of shares is generally seen as a good sign, indicating confidence in the company's prospects. However, it's a relatively small transaction.

Positives

• A director's purchase of shares can be seen as a positive signal of confidence in the company's future prospects.

Industry Context

Insider transactions are closely watched by investors as they can provide insights into management's view of the company's value and future performance. This purchase by a director may be interpreted as a positive sign.

Comparison to Industry Standards

• Director share purchases are common across the industry and are often seen as a positive sign of confidence in the company's future.
• The size of this purchase is relatively small compared to some insider transactions, but it is still a notable event for Anixa Biosciences.

Stakeholder Impact

• The share purchase may have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Anixa Biosciences, insider trading, share purchase, director, common stock, ownership, Lewis H. Titterton Jr.